To provide more definitive data on whether T-type inhibition is useful in treating Dravet syndrome, a future study could assess the effects of selective T-type calcium channel inhibitors with improved oral pharmacokinetic properties in the Scn1a+/− mice. Here, SCN1A is linked to Dravet syndrome.